APYX
Apyx Medical Corp
Next earnings Aug 5, 2026 (before open) · consensus $-0.09 EPS, $13.6M rev
Last earnings +21.9% on 2026-05-07
$4.50
▲ +7.91%$4.50▲ +125.00%
over 1Y
L $1.75EODHDH $4.86
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.9%
1W+12.2%
1M+15.4%
3M+23.6%
YTD+28.6%
1Y+125.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Revenue grew 9.9% YoY; but unprofitable (net margin -21.2%).
Revenue (FY2025) $52.8M · FY2025
Apyx Medical Corp shows $52.8M in FY2025 revenue (+9.9% YoY), a -21.2% net margin, and -77.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $48.5M | $44.5M | $52.3M | $48.1M | $52.8M |
| Gross profit | $33.6M | $29.1M | $33.8M | $29.4M | $33.0M |
| Operating income | -$14.4M | -$23.6M | -$17.3M | -$18.8M | -$6.45M |
| Net income | -$15.2M | -$23.2M | -$18.7M | -$23.5M | -$11.2M |
| Diluted EPS | -$0.44 | -$0.67 | -$0.54 | — | — |
| Net margin | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$191M
EV / EBITDA—
EV / Sales3.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.0%
FCF yield-4.8%
Quality & risk
ROIC (est.)-10.3%
Free cash flow-$9.12M
Total debt$34.8M
Net cash-$3.11M
Altman Z-Score1.62 distress
Piotroski F-Score5/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+10.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗DEF 14APeriod ending 2025-12-312026-06-26open ↗4Period ending 2026-06-152026-06-17open ↗8-KPeriod ending 2026-06-112026-06-17open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗SDFiling2026-06-01open ↗
Frequently asked
- Is Apyx Medical Corp (APYX) a buy?
- APYX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 9.9% YoY; but unprofitable (net margin -21.2%).
- What is Apyx Medical Corp's quality score?
- APYX scores 53.78431372549019/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000719135, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:53:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.